Impact BioMedical Inc. (NYSE American: IBO)’s Post

How can we avoid disrupting the golden age of medicine with ineffective policies? John F. Crowley, CEO of Biotechnology Innovation Organization, joins a16z general partner, Jorge Conde, to discuss how poorly designed policies could hinder both innovation and access to critical treatments. When considering the breakthroughs in the biotech industry, it’s essential to balance regulatory measures to foster growth without unintended consequences. The duo emphasize that the focus must be on facilitating patient-centered innovation, removing barriers, and ensuring no patient is left without necessary medicines. Listen on Raising Health: https://lnkd.in/g26nuCYX

Check out a discussion with BIO's President & CEO John F. Crowley and a16z Bio + Health's Jorge Conde about the importance of balanced policies for biotech innovation.

The BioNTX Facilities Advisory Committee joined with NexPoint and the Texas Research Quarter to welcome industry and regional innovators for a dynamic panel discussion on the pivotal role that North Texas plays in the future of healthcare and biotechnology innovation. Leaders highlighted the rapidly growing capabilities and incredible advancements happening locally, and addressed the challenges the region faces as it becomes increasingly competitive with other U.S. Biotech Hubs.   BioNTX is wholly committed to fostering collaboration and driving forward the groundbreaking research happening in our region to improve the State’s economic development and patient outcomes. Together, we continue to push the boundaries and work together towards a healthier tomorrow! Learn more about the BioNTX Facilities Advisory Committee https://lnkd.in/gpJuygEC #innovation #lifescience #biotechnology #biotech #biomanufacturing #healthcare #lifesciences #research #bioscience #facilities #Texas #TRQ #Texas #TexasResearchQuarter #NorthTexas

CEO REMUNERATION REPORT - ASX Health & Biotechnology The 9th edition of Wexford Hayes annual CEO Remuneration Report is here. Trusted by Boards, CEOs, and investors across the sector, this report delivers valuable insights into the latest remuneration trends shaping the health and biotechnology landscape. 🎥 Watch the attached video for key insights. If you'd like a copy, please get in touch. www.wexfordhayes.com #Biotechnology #healthcare #Remuneration #Boards #CEO

🔬 Implementing alternative methods for adventitious agents can slash >90% of testing time and realize cost savings of up to $5 million per product , but their adoption has been slow. 📰 The BioPhorum paper ‘A Structured Approach For The Evaluation, Validation And Implementation Of Nat-Based Mycoplasma Detection Methods’, published in 2023 by the Technology Strategy Phorum has been summarised by Life Science Connect and details a best practice 9 step framework for adoption of NAT-Based Mycoplasma Detection Methods. #Mycoplasma #BioPhorum Life Science Connect Bioprocess Online https://lnkd.in/e7TM-7Tg ✍🏻 Authors: ✍🏾 ·      BioMérieux Félix A MONTERO-JULIAN PhD ·      Lonza Antonietta Corrado, Eva Tur García ·      Merck (Health Care Business Sector) Cristina Barbirato ·      Merck (Life Science Business Sector) Rob Goodier , Donna McMutrie ·      Novo Nordisk Annette Jørgensen ·      Pall Biotech Morven McAlister ·      Roche/Genentech Sven Deutschmann, Kevin McCarthy ·      Sanofi Thierry Bonnevay ·      Sartorius Stedim Dr. Miriam Dormeyer ·      Thermo Fisher Scientific Mike Brewer ☑ Reviewers: ☑ ·      Asahi Kasei Daniel Strauss ·      BioMérieux Philippe GADAL, Arnaud PARIS - Pharma Quality Control ·      Bioprocessing Technology Institute, Agency for Science, Technology and Research Andre Choo ·      FUJIFILM Diosynth Biotechnologies WILLIAMS KWAME NKRUMAH, LLM ·      Janssen Karen De Roy ·      Novo Nordisk Corinna Cavan Pedersen

We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said #3. We are ambitious: We are driven by our shared mission to discover, develop and deliver impactful medicines to patients using cutting edge science. We are motivated to push boundaries and think big as we tackle challenges we confront as a company. We take a proactive approach towards research, and we are intentional in setting our short-term and long-term goals. Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf #innovation #biotech #drugdiscovery

Save the date

Accelerate breakthroughs. Unleash life-saving therapies. At Bios Health Group, we're not just a partner; we're your strategic ally in the journey of life sciences innovation. Our mission? To empower biotech and life science visionaries like you to turn groundbreaking ideas into reality. 🌱 Whether you're a pioneering company or an investor with a passion for progress, we've got your back every step of the way. Let's revolutionize healthcare together! www.bioshealthgroup.com #biotechnology #clinicaldevelopment #drugdevelopment #biotech  #BiosHealthInnovates #HealthcareRevolution #InnovationJourney #CollaborateForChange #ClinicalTrialsAdvancement #PatientDiversity  #LifeSciences #Biotech #Innovation #Healthcare #Research #Biomedical #MedTech #Investment #Science #Tech #HealthTech #Pharma

🚀 Turning Point for metaBIX Biotech: Tilting the Balance Toward Innovation 🚀 Since our launch in July 2022, metaBIX Biotech has followed an upward trajectory, not only achieving financial milestones but also having a significant impact on animal production. 🌟 Key Achievements: Strategic Expansion: Why are we at a turning point? 🤝 Established a crucial partnership in #Asia to expand our footprint in the #globalmarket. 🤝 Reached an agreement with Farma Animal to start pilot projects in #Brazil, strengthening our presence in Latin America. 🛬 Preparing to expand in the #UnitedStates to capitalize on opportunities in one of the world’s most dynamic markets. 🎯 Our Goal: Our target is to exceed $100 million in sales by 2028, significantly contributing to the improvement of global health. These achievements are not just milestones; they are testimonies of our disruptive technology and our tireless commitment to innovation. At metaBIX Biotech, we do not just keep pace with the industry, we define it. #Innovation #GlobalmetaBIXBiotech #Biotechnology The Ganesha Lab ANII BID Lab

Rooting for BioAge Labs and the most wonderful CEO in longevity biotechnology Kristen Fortney! I will buy a little once they trade (not an investment advice in any way - I am just a fan of the company and their business model). IMHO, the best way to work in aging is to find several promising targets, in-license several safe and super promising programs and start Phase IIs. It also helps a lot if you are in a hot therapeutic area. But the next big therapeutic area - age-related biological processes and kudos to Eli Lilly for placing big bets on this area. #longevity